Welcome to our dedicated page for Aditxt SEC filings (Ticker: ADTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a company that engineers immune-tolerance platforms like Aditxt means wading through dense scientific disclosures, layered risk factors, and frequent R&D updates. Whether you need “Aditxt 8-K material events explained” before a clinical milestone or want “Aditxt insider trading Form 4 transactions” to gauge management’s conviction, the raw SEC feed can feel impenetrable.
Stock Titan solves that problem. Our AI instantly converts every filing—from an “Aditxt quarterly earnings report 10-Q filing” to an “Aditxt annual report 10-K simplified”—into clear briefs that spotlight transplant-tolerance progress, Adimune trial costs, and AditxtScore commercialization timelines. You’ll also find “Aditxt SEC filings explained simply” in a single dashboard. Real-time alerts flag “Aditxt Form 4 insider transactions real-time,” so you see executive buys or sales the moment they post. Need deeper context? AI-generated redlines map pipeline spending, patent updates, and cash-runway changes across periods.
Professionals use these insights to:
- Compare immunotherapy R&D spend quarter over quarter
- Monitor “Aditxt proxy statement executive compensation” against shareholder returns
- Spot dilution risk highlighted in capital-raise 8-Ks
Because every document is cross-linked, “understanding Aditxt SEC documents with AI” takes minutes, not hours. Historical dashboards overlay revenue guidance with “Aditxt earnings report filing analysis,” while footnote extraction pulls trial enrollment numbers straight from the MD&A. If your strategy hinges on timely signals—from “Aditxt executive stock transactions Form 4” to emergent licensing deals—this page delivers the complete picture as soon as EDGAR releases it.
Aditxt has reported several significant financial transactions in this 8-K filing. Two senior executives provided short-term loans to the company: CEO Amro Albanna ($90,000) and CIO Shahrokh Shabahang ($100,000). These unsecured promissory notes carry a 7.5% interest rate and are due by July 20, 2025.
Additionally, the company issued a warrant to an unnamed consultant as part of a new marketing services agreement. Key warrant terms include:
- Right to purchase up to 600,000 shares of common stock
- Exercise price of $2.00 per share
- Two-year term
- Ownership limitation of 4.99% (or 9.99% at holder's election)
Both the promissory notes and warrant were issued under Section 4(a)(2) Securities Act exemption. The company, listed on Nasdaq as ADTX, is classified as an emerging growth company. These transactions suggest potential cash flow challenges and efforts to enhance investor relations.
Aditxt has filed an S-1 registration statement for the resale of up to 50 million shares of common stock under a $150 million purchase agreement with Seven Knots. The company has already sold 932,549 shares for approximately $23.9 million under this agreement.
Key business highlights:
- Founded in 2017, Aditxt focuses on transforming healthcare innovations into commercial products across immune health, precision health, population health, women's health, and neurologic health
- Business model involves securing innovations through licensing/acquisition, providing resources for development, and monetizing through commercialization
- Current commercial programs include Adimune (immune modulation technology) and Pearsanta (precision diagnostics)
- Company operates as a non-accelerated filer, smaller reporting company, and emerging growth company
The stock currently trades on Nasdaq under symbol ADTX at $1.42 per share (as of June 18, 2025). The company has implemented a digital asset treasury strategy that includes potential bitcoin investments. Notable partnerships include Stanford University and Mayo Clinic.
FAQ
What is the current stock price of Aditxt (ADTX)?
What is the market cap of Aditxt (ADTX)?
What is the primary focus of Aditxt Inc?
What are the key product programs of Aditxt Inc?
How does Aditxt Inc generate revenue?
What is the significance of immune tolerance in Aditxt Inc's work?
How does Aditxt Inc differentiate itself from other biotech companies?
What role does research and development play at Aditxt Inc?
How do the products of Aditxt Inc impact patient care?
What industry sectors does Aditxt Inc operate within?
